fbpx

5:30 – 5:45

GS2-01. Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer

Social Share

× How can I help you?